We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session

Upper GI
6010
Poster (digital)
Clinical
Local control still a challenge in post-SBRT advanced Pancreatic cancer - A single institute series
Rahul Krishnatry, India
PO-1282
Stereotactic Body Radiotherapy (SBRT) for liver tumors – An analysis of Dose volume effects
Jeevi Selvarajan, India
PO-1283
Factors predicting benefits of proton therapy in liver tumors of ≤5cm based on the hepatic toxicity
Yusuke Uchinami, Japan
PO-1284
Clinical impact of carbon ion radiotherapy for hepatocellular carcinoma with Child-Pugh B cirrhosis
Yuichi Hiroshima, Japan
PO-1285
Skeletal muscle measured at T12 is a prognostic biomarker in oesophageal cancer patients
Donal McSweeney, United Kingdom
PO-1286
FDG PET/CT AS PREDICTIVE AND PROGNOSTIC FACTOR IN ESOPHAGEAL CANCER TREATED WITH MULTIMODAL THERAPY
Eleonora Ferrara, Italy
PO-1287
Dose-Painting Sbrt On Tumor-Vessel And Duodenal Interface For Pancreatic Cancer: Dosimetric Analysis
Luciana Caravatta, Italy
PO-1288
Toxicity and treatment outcomes in dose escalated radiotherapy for upper third oesophageal carcinoma
May Myat Noe Win, United Kingdom
PO-1289
Does setup and internal margin differ on verification modality and location in carcinoma oesophagus?
Nelesh Aggarwal, India
PO-1290
Acute toxicity and clinical outcome in carcinoma middle oesophagus treated with definitive CTRT
Shreya Jalota, India
PO-1291
Stereotactic radiotherapy after chemotherapy in patients with locally advanced pancreatic cancer
Charlotte LE ROY, France
PO-1292
A dosimetric evaluation of 4D-CT vs 3D-CT in mid and lower third upper GI Patients
Bethan Stewart-Thomson, United Kingdom
PO-1293
clinical prognostic factors for esophageal cancer treated with definitive chemo-radiotherapy
Douglas Castro, Brazil
PO-1294
Prognostic role of ALBI-T in locoregional advanced hepatocellular carcinoma (BCLC-C) undergoing SBRT
Deepti Sharma, India
PO-1295
Hemostatic Radiotherapy for Gastric Cancer: Relationship Between MR Images and Tumor Markers
Osamu Tanaka, Japan
PO-1296
Neoadjuvant chemoradiotherapy for esophageal cancer – a single institution experience
Ajra Secerov Ermenc, Slovenia
PO-1297
HEMATOLOGICAL & BIOCHEMICAL CHANGES DURING AND POST SBRT FOR HCC : AN INSTITUTIONAL STUDY
Shipra Gupta, India
PO-1298
Charlson Comorbidity Index for patients selection in definitive chemoradiation for anal carcinoma
Sara Lucidi, Italy
PO-1299
Stereotactic body radiotherapy in the treatment of Pancreatic carcinoma
Ahmed Gawish, Germany
PO-1300
The efficacy of the stereotactic body radiation in the management of the cholangiocarcinoma
Ahmed Gawish, Germany
PO-1301
Toxicity of the gallbladder with stereotactic body radiotherapy for liver tumors
Ahmed Gawish, Germany
PO-1302
Prospective phase 2 study of induction FOLFIRINOX followed by chemoradiation in LA-Pancreatic Cancer
Gian Marco Petrianni , Italy
PO-1303
Impact of blood parameters and normal tissue dose on overall survival in esophageal cancer patients
Esther Troost, Germany
PO-1304
Muscle Loss After Stereotactic Body Radiotherapy Predicts Worse Survival in Hepatocellular Carcinoma
Jen-Fu Yang, Taiwan
PO-1305
Impacts and consequences of spleen irradiation after adjuvant chemoradiation for stomach cancer
Shing Fung Lee, Singapore
PO-1306
High-dose stereotactic ablative body radiotherapy for locally advanced pancreatic cancer
Hye In Lee, Korea Republic of
PO-1307
Feasibility of endoscopic fiducial marker implantation in the stomach for use in image-guided RT
Margot Bleeker, The Netherlands
PO-1308
Safety and efficacy of neoadjuvant stereotactic ablative radiotherapy (SABR) in pancreatic cancer
Hyun-Cheol Kang, Korea Republic of
PO-1309
Frail and Elderly Patients with Oesophageal Cancer: the challenge of hypofractionated radiotherapy.
Letizia Deantonio, Switzerland
PO-1310